Solesence (SLSN) Price & Analysis

Compare

45 Followers

SLSN Stock Chart & Stats

$2.17

Market closed

$2.17

Day’s Range― - ―

52-Week Range$1.16 - $16.56

Previous CloseN/A

VolumeN/A

Average Volume (3M)50.43K

Market Cap

$83.23M

Enterprise Value$107.99M

Total Cash (Recent Filing)$429.00K

Total Debt (Recent Filing)$25.18M

Price to Earnings (P/E)84.3

Beta1.41

Next Earnings

Apr 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding70,536,840

10 Day Avg. Volume39,901

30 Day Avg. Volume50,427

Financial Highlights & Ratios

PEG Ratio-0.20

Price to Book (P/B)10.18

Price to Sales (P/S)2.91

P/FCF Ratio-58.81

Enterprise Value/Market Cap1.30

Enterprise Value/Revenue1.74

Enterprise Value/Gross Profit7.01

Enterprise Value/Ebitda32.72

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High ROE & Reduced LeverageSolesence's high ROE indicates effective use of shareholder capital to generate profits, while a reduced debt-to-equity ratio lowers interest burden and financial risk. Together these durable balance-sheet improvements increase capacity to fund R&D and partnerships and better absorb industry cyclical shocks.

Proprietary B2B Model & PartnershipsA B2B model focused on proprietary formulations and licensing builds recurring revenue from long-term contracts and deep client integration. Durable relationships with established brands create switching costs, steady order pipelines, and higher margin opportunities from customized, technical solutions.

Large Patent Portfolio & Leadership LegacyOwning an extensive patent portfolio creates a sustainable competitive moat around formulations and delivery systems, enabling licensing and premium pricing. Combined with experienced leadership and retained founder consulting, intellectual property and institutional knowledge support long-term product differentiation.

Bears Say

Revenue Decline And Recent Quarter DropSustained revenue weakness reduces scale economics and heightens reliance on a few customers. A multi-quarter decline undermines margin leverage and raises questions about product-market fit and client inventory cycles, requiring meaningful commercial recovery to restore long-term growth trajectories.

Negative Operating Cash FlowConsistent negative operating cash flow constrains the company's ability to self-fund R&D, capex, and working capital, forcing dependence on external financing. Even with FCF growth metrics, a negative OCF coverage ratio signals structural cash-generation issues that can impair strategic flexibility.

Margin Compression From Manufacturing IssuesA pronounced drop in gross margin driven by production inefficiencies and facility upgrades raises recurring cost risk and lengthens payback on operational fixes. If labor and OEE improvements don't fully restore prior margins, profitability and reinvestment capacity will remain constrained over the medium term.

Solesence News

Solesence appoints Yoolie Park as VP, brand partnerships

Solesence has appointed Yoolie Park as Vice President of Brand Partnerships. In this role, Park will lead strategic...

7d ago

SLSN

Solesence Appoints New Director After CEO Retirement

Solesence ( ($SLSN) ) just unveiled an announcement. On November 22, 2025, Solesence, Inc. entered into a Consulting...

3M ago

SLSN

Solésence Reports Q3 2025 Results Amid Strategic Changes

Nanophase Technologies Corp ( ($SLSN) ) has released its Q3 earnings. Here is a breakdown of the information...

4M ago

SLSN

Nanophase Technologies Corp’s Earnings Call: Challenges and Optimism

Nanophase Technologies Corp (($SLSN)) has held its Q3 earnings call. Read on for the main highlights of the...

4M ago

SLSN

Solesence reports Q3 EPS (2c) vs 4c last year

Reports Q3 revenue $14.5M vs $16.9M last year. “As part of our ongoing transformation, Solesence implemented several strategic...

4M ago

SLSN

Solesence appoints Yoana Dvorzsak as VP, innovation, product integrity

Solesence appointed Yoana Dvorzsak to the newly created role of Vice President of Innovation and Product Integrity to...

4M ago

SLSN

Solesence Reaches Settlement Agreement with Solarium Brands

Solesence ( ($SLSN) ) has shared an announcement. On October 31, 2025, Solésence, Inc. and its subsidiary Solésence,...

4M ago

SLSN

Solesence Announces Leadership Changes Amid Strategic Shift

An update from Solesence ( ($SLSN) ) is now available. On September 3, 2025, Solésence, Inc. announced significant...

6M ago

SLSN

Solesence appoints Kevin Cureton as president, CEO

Solesence announced strategic changes to its executive leadership. Kevin Cureton will assume the role of President and CEO....

6M ago

SLSN

Solesence Holds Successful Annual Shareholder Meeting

Solesence ( ($SLSN) ) has provided an announcement. On August 28, 2025, Solésence, Inc. held its Annual Meeting...

6M ago

SLSN

Solésence Reports Strong Q2 2025 Revenue Growth

Nanophase Technologies Corp ( ($SLSN) ) has released its Q2 earnings. Here is a breakdown of the information...

7M ago

SLSN

Solesence to join Russell 3000, Russell 2000 Indexes

Solesence will be added as a member of the broad-market Russell 3000 and small-cap Russell 2000 Indexes, effective...

8M ago

SLSN

Solesence expands debt facilities

Solesence entered into amendments on May 27, 2025 to its existing loan agreements, providing increased borrowing capacity to...

9M ago

SLSN

Solésence Expands Loan Agreement for Growth Flexibility

Solesence ( ($SLSN) ) just unveiled an announcement. On May 27, 2025, Solésence, Inc. amended its existing loan...

9M ago

SLSN

SLSN FAQ

What was Solesence’s price range in the past 12 months?

Solesence lowest stock price was $1.16 and its highest was $16.56 in the past 12 months.

What is Solesence’s market cap?

Solesence’s market cap is $83.23M.

When is Solesence’s upcoming earnings report date?

Solesence’s upcoming earnings report date is Apr 01, 2026 which is in 27 days.

How were Solesence’s earnings last quarter?

Solesence released its earnings results on Nov 11, 2025. The company reported -$0.016 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.016.

Is Solesence overvalued?

According to Wall Street analysts Solesence’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Solesence pay dividends?

Solesence does not currently pay dividends.

What is Solesence’s EPS estimate?

Solesence’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Solesence have?

Solesence has 70,536,840 shares outstanding.

What happened to Solesence’s price movement after its last earnings report?

Solesence reported an EPS of -$0.016 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -24.199%.

Which hedge fund is a major shareholder of Solesence?

Currently, no hedge funds are holding shares in SLSN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Solesence Stock Smart Score

Underperform

Fundamentals

Return on Equity

6.60%

Trailing 12-Months

Asset Growth

12.36%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Solesence

Solesence (SLSN) is a biotechnology company focused on developing innovative solutions for the cosmetics and personal care industries. The company specializes in harnessing the power of natural ingredients to create advanced formulations that enhance the performance and sensory attributes of beauty products. With a strong emphasis on sustainability and efficacy, Solesence serves a diverse range of clients, including leading beauty brands and manufacturers, by providing proprietary technology and products that improve product stability, texture, and delivery of active ingredients.

Solesence (SLSN) Earnings & Revenues

Historic Earnings Reports

SLSN Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call reflects a challenging quarter with a notable decline in revenue and profitability. However, the company highlights strategic operational improvements and leadership changes aimed at driving future growth. Although the short-term financials are negative, there is optimism about long-term growth and market leadership.View all SLSN earnings summaries